ImmuCell (NASDAQ:ICCC) Releases Earnings Results

ImmuCell (NASDAQ:ICCC) announced its quarterly earnings data on Tuesday. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, Zacks reports. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%.

ImmuCell Stock Up 1.6 %

ImmuCell stock traded up $0.08 during trading on Tuesday, reaching $5.10. The stock had a trading volume of 2,267 shares, compared to its average volume of 5,716. The company has a quick ratio of 1.44, a current ratio of 3.11 and a debt-to-equity ratio of 0.36. ImmuCell has a 52-week low of $3.34 and a 52-week high of $5.82. The stock has a market cap of $45.45 million, a PE ratio of -10.20 and a beta of 0.54. The business has a 50 day moving average price of $5.11 and a 200 day moving average price of $4.26.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.